DANAHER CORP /DE/DHR
DANAHER CORP /DE/ Financial Overview 2021–2025
Updated Jul 10, 2026After watching core sales plummet by 10.0% in FY2023 as pandemic-era diagnostics demand evaporated, Danaher executed a relentless portfolio transformation culminating in the $9.9 billion pending acquisition of Masimo in FY2025. The company operates as a strict capital allocator, successfully navigating a prolonged bioprocessing slump by spinning off its legacy industrial water assets and buying up high-margin platforms like Abcam for $5.6 billion.
The company's financial trajectory reflects a deliberate, albeit painful, return to normalized growth. Diluted earnings per share compressed from $8.61 in FY2021 to $5.03 by FY2025 as the highly profitable COVID-19 testing boom faded. Despite this bottom-line contraction, underlying business health stabilized over time. Total sales reached $24.57 billion with core sales growing 2.0% in FY2025. The company defended its profitability to deliver a 19.1% operating profit margin for the year, supported by cost-saving initiatives and the efficiency of the Danaher Business System. Management also actively managed its capital structure when growth stalled, executing a massive $6.0 billion in stock buybacks during a flat-growth FY2024.
Investors paid a distinct premium for this strategic transition into a pure-play medical and life sciences business. At the close of FY2025, the market valued the company at a $161.8 billion market capitalization, with the stock trading at $228.92 and carrying a steep price-to-earnings ratio of 45.3x.
Recent Developments (Q4 2025 and Q1 2026)
In Q1 2026, Danaher delivered a 3.5% total sales increase to $5.95 billion, boosted largely by a 3.0% currency tailwind. Core sales expanded a modest 0.5%. Despite this sluggish top-line expansion, operating profit margins improved 40 basis points to 22.6%, driving net earnings up to $1.0 billion, or $1.45 per share. To support corporate liquidity, the company secured a new $5.0 billion revolving credit facility in April 2026. Additionally, Dr. Jessica Mega retired from the Board of Directors in February 2026.
Bulls highlight the Biotechnology segment's robust 7.0% core sales growth driven by strong bioprocessing and consumables demand. Bears point to the Diagnostics segment's 4.0% core sales decline caused by ongoing pricing pressures in China and lower respiratory test volumes. Trading at a steep 38.5x earnings as of the Q1 2026 reporting date, the stock appears richly valued relative to its near-term, low-single-digit growth profile.
What to watch: stabilization of diagnostics pricing within the Chinese market; progress on antitrust approvals for pending transactions.
Rev
$24.57B
FY2025
NI
$3.61B
FY2025
EPS
$5.07
FY2025
OCF
$6.42B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
DANAHER CORP /DE/ 8-K Report, Financial Obligation (Jun 3, 2026)
Danaher Corporation (DHR) announced on June 3, 2026, the closing of a private placement of senior unsecured notes totaling CHF 2,682,880,000. These notes are issued by its subsidiary, DH Masi Finance Inc., and are fully and unconditionally guaranteed by Danaher. The issuance comprises seven series of notes with varying maturities ranging from 2031 to 2056 and fixed interest rates from 1.65% to 2.51%. The net proceeds from this debt offering are intended for general corporate purposes, including working capital, potential acquisitions, and share repurchases. The terms of the note purchase agreement are consistent with Danaher's existing debt obligations and include customary covenants and events of default. This transaction diversifies Danaher's funding sources and extends its debt maturity profile.
DANAHER CORP /DE/ 8-K Report, Executive Changes (May 7, 2026)
Danaher Corporation (DHR) filed an 8-K on May 7, 2026, detailing outcomes from its Annual Meeting of Shareholders held on May 5, 2026. The most significant event for investors is the shareholder approval of the Amended and Restated Danaher Corporation Omnibus Incentive Plan. This plan was updated to increase the share reserve by 20 million shares of Common Stock and extend its term to May 5, 2036, indicating continued focus on executive and employee compensation through equity incentives. Additionally, the filing confirms the election of all eleven director nominees and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Shareholders also approved, on an advisory basis, the compensation of the company's named executive officers. These approvals reflect shareholder confidence in the company's governance and executive compensation strategies.
DANAHER CORP /DE/ 8-K Report, Material Agreement (Apr 29, 2026)
Danaher Corporation (DHR) has filed an 8-K detailing the issuance of €2.98 billion (approximately) in senior notes. This offering includes both floating-rate notes maturing in 2028 and fixed-rate notes with maturities in 2030, 2034, and 2038, carrying interest rates of 3.250%, 3.625%, and 4.000% respectively. The primary stated use of these proceeds is to fund a portion of the cash consideration and associated costs for the proposed acquisition of Masimo Corporation. Danaher also retains the flexibility to use a portion of the proceeds for general corporate purposes, including debt refinancing and working capital. This debt issuance provides significant capital to support Danaher's strategic growth initiatives, particularly the pending Masimo acquisition. The notes are unsecured senior indebtedness, ranking equally with existing unsecured senior debt. Investors should note the early redemption provisions, including a potential "Par Call" option for fixed-rate notes and a special mandatory redemption if the Masimo Acquisition is not consummated, which would trigger a redemption at 101% of the principal amount. Additionally, a change of control triggering event would allow noteholders to demand repurchase at 101%.
DANAHER CORP /DE/ 8-K Report, Financial Results (Apr 21, 2026)
Danaher Corporation (DHR) filed an 8-K on April 21, 2026, to report its financial results for the first quarter ended March 27, 2026. The filing includes a press release, furnished as Exhibit 99.1, which details the company's performance during the quarter. Investors should refer to this press release for specific financial figures, including revenue, earnings, and any segment-specific performance. This report is important as it provides the official update on Danaher's operational and financial standing at the beginning of 2026. While the 8-K itself is a notification and incorporates the press release, it's crucial for stakeholders to review the actual financial data and management commentary within the furnished press release to understand the company's current trajectory, profitability, and outlook.
DANAHER CORP /DE/ 8-K Report, Material Agreement (Apr 17, 2026)
Danaher Corporation (DHR) has entered into a new $5.0 billion 364-day revolving credit facility, maturing on April 15, 2027. This facility, with Bank of America, N.A. as Administrative Agent and a syndicate of lenders, is designed to provide liquidity support for Danaher's U.S. dollar-denominated commercial paper program and for general corporate purposes. The agreement offers flexibility, including the option to convert outstanding loans into term loans one year after the scheduled termination date, subject to certain conditions and fees. This strategic move bolsters Danaher's financial flexibility and operational capacity.
View all 8-K filings →